Neutral impactResults
Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business
Business Standard 2 hrs ago·26 Oct 2026, 12:10 pm
The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.
Affected stocks
Neutral1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Mankind Pharma (MANKIND).
- Category: Results.
Why it matters
A routine update for Mankind Pharma. Use the price and stock snapshot to gauge how the market is responding.
